Quell Therapeutics

Luke Henry, Chief Business Officer 

Oct. 11 | 11:30am | Oxford Biomedica Ballroom 

London, UK 


In-person Presentation 

Quell Therapeutics is leading the emerging field of using engineered T-regulatory (Treg) cell therapies that aim to harness, direct, and optimize their immune suppressive properties to address serious medical conditions driven by the immune system. Quell is leveraging its pioneering phenotype lock technology, unique multi-modular engineering platform, and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency, and stability than earlier generations of Treg cell therapy approaches. Quell’s lead clinical candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. 


By using this website you agree to accept our Privacy Policy and Terms & Conditions